Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Emiliano Cocco, F. Javier Carmona, Pedram Razavi, Helen H. Won, Yanyan Cai, Valentina Rossi, Carmen Chan, James Cownie, Joanne Soong, Eneda Toska, Sophie G. Shifman, Ivana Sarotto, Peter Savas, Michael J. Wick, Kyriakos P. Papadopoulos, Alyssa Moriarty, Richard E. Cutler, Francesca Avogadri-Connors, Alshad S. Lalani, Richard P. BryceSarat Chandarlapaty, David M. Hyman, David B. Solit, Valentina Boni, Sherene Loi, José Baselga, Michael F. Berger, Filippo Montemurro, Maurizio Scaltriti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mutations in ERBB2, the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of "HER2-negative" (not ERBB2 amplified) tumors but are rare in "HER2-positive" (ERBB2 amplified) breast cancer. We analyzed DNA-sequencing data from HER2-positive patients and used cell lines and a patient-derived xenograft model to test the consequence of HER2 mutations on the efficacy of anti-HER2 agents such as trastuzumab, lapatinib, and neratinib, an irreversible pan-EGFR inhibitor. HER2 mutations were present in ~7% of HER2-positive tumors, all of which were metastatic but not all were previously treated. Compared to HER2 amplification alone, in both patients and cultured cell lines, the co-occurrence of HER2 mutation and amplification was associated with poor response to trastuzumab and lapatinib, the standard-of-care anti-HER2 agents. In mice, xenografts established from a patient whose HER2-positive tumor acquired a D769Y mutation in HER2 after progression on trastuzumab-based therapy were resistant to trastuzumab or lapatinib but were sensitive to neratinib. Clinical data revealed that six heavily pretreated patients with tumors bearing coincident HER2 amplification and mutation subsequently exhibited a statistically significant response to neratinib monotherapy. Thus, these findings indicate that coincident HER2 mutation reduces the efficacy of therapies commonly used to treat HER2-positive breast cancer, particularly in metastatic and previously HER2 inhibitor-treated patients, as well as potentially in patients scheduled for first-line treatment. Therefore, we propose that clinical studies testing the efficacy of neratinib are warranted selectively in breast cancer patients whose tumors carry both amplification and mutation of ERBB2/HER2.

Original languageEnglish
Article numbereaat9773
JournalScience Signaling
Volume11
Issue number551
DOIs
Publication statusPublished - Oct 9 2018

Fingerprint

Bearings (structural)
Amplification
Tumors
Breast Neoplasms
Mutation
Epidermal Growth Factor Receptor
Heterografts
Cells
Neoplasms
Gene encoding
erbB-1 Genes
Cell Line
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
Standard of Care
DNA Sequence Analysis
Trastuzumab
DNA
Testing
Cultured Cells
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Cocco, E., Carmona, F. J., Razavi, P., Won, H. H., Cai, Y., Rossi, V., ... Scaltriti, M. (2018). Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 11(551), [eaat9773]. https://doi.org/10.1126/scisignal.aat9773

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). / Cocco, Emiliano; Carmona, F. Javier; Razavi, Pedram; Won, Helen H.; Cai, Yanyan; Rossi, Valentina; Chan, Carmen; Cownie, James; Soong, Joanne; Toska, Eneda; Shifman, Sophie G.; Sarotto, Ivana; Savas, Peter; Wick, Michael J.; Papadopoulos, Kyriakos P.; Moriarty, Alyssa; Cutler, Richard E.; Avogadri-Connors, Francesca; Lalani, Alshad S.; Bryce, Richard P.; Chandarlapaty, Sarat; Hyman, David M.; Solit, David B.; Boni, Valentina; Loi, Sherene; Baselga, José; Berger, Michael F.; Montemurro, Filippo; Scaltriti, Maurizio.

In: Science Signaling, Vol. 11, No. 551, eaat9773, 09.10.2018.

Research output: Contribution to journalArticle

Cocco, E, Carmona, FJ, Razavi, P, Won, HH, Cai, Y, Rossi, V, Chan, C, Cownie, J, Soong, J, Toska, E, Shifman, SG, Sarotto, I, Savas, P, Wick, MJ, Papadopoulos, KP, Moriarty, A, Cutler, RE, Avogadri-Connors, F, Lalani, AS, Bryce, RP, Chandarlapaty, S, Hyman, DM, Solit, DB, Boni, V, Loi, S, Baselga, J, Berger, MF, Montemurro, F & Scaltriti, M 2018, 'Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)', Science Signaling, vol. 11, no. 551, eaat9773. https://doi.org/10.1126/scisignal.aat9773
Cocco, Emiliano ; Carmona, F. Javier ; Razavi, Pedram ; Won, Helen H. ; Cai, Yanyan ; Rossi, Valentina ; Chan, Carmen ; Cownie, James ; Soong, Joanne ; Toska, Eneda ; Shifman, Sophie G. ; Sarotto, Ivana ; Savas, Peter ; Wick, Michael J. ; Papadopoulos, Kyriakos P. ; Moriarty, Alyssa ; Cutler, Richard E. ; Avogadri-Connors, Francesca ; Lalani, Alshad S. ; Bryce, Richard P. ; Chandarlapaty, Sarat ; Hyman, David M. ; Solit, David B. ; Boni, Valentina ; Loi, Sherene ; Baselga, José ; Berger, Michael F. ; Montemurro, Filippo ; Scaltriti, Maurizio. / Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). In: Science Signaling. 2018 ; Vol. 11, No. 551.
@article{cf123b3678fa4a4fa6a477c6be7246ad,
title = "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)",
abstract = "Mutations in ERBB2, the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of {"}HER2-negative{"} (not ERBB2 amplified) tumors but are rare in {"}HER2-positive{"} (ERBB2 amplified) breast cancer. We analyzed DNA-sequencing data from HER2-positive patients and used cell lines and a patient-derived xenograft model to test the consequence of HER2 mutations on the efficacy of anti-HER2 agents such as trastuzumab, lapatinib, and neratinib, an irreversible pan-EGFR inhibitor. HER2 mutations were present in ~7{\%} of HER2-positive tumors, all of which were metastatic but not all were previously treated. Compared to HER2 amplification alone, in both patients and cultured cell lines, the co-occurrence of HER2 mutation and amplification was associated with poor response to trastuzumab and lapatinib, the standard-of-care anti-HER2 agents. In mice, xenografts established from a patient whose HER2-positive tumor acquired a D769Y mutation in HER2 after progression on trastuzumab-based therapy were resistant to trastuzumab or lapatinib but were sensitive to neratinib. Clinical data revealed that six heavily pretreated patients with tumors bearing coincident HER2 amplification and mutation subsequently exhibited a statistically significant response to neratinib monotherapy. Thus, these findings indicate that coincident HER2 mutation reduces the efficacy of therapies commonly used to treat HER2-positive breast cancer, particularly in metastatic and previously HER2 inhibitor-treated patients, as well as potentially in patients scheduled for first-line treatment. Therefore, we propose that clinical studies testing the efficacy of neratinib are warranted selectively in breast cancer patients whose tumors carry both amplification and mutation of ERBB2/HER2.",
author = "Emiliano Cocco and Carmona, {F. Javier} and Pedram Razavi and Won, {Helen H.} and Yanyan Cai and Valentina Rossi and Carmen Chan and James Cownie and Joanne Soong and Eneda Toska and Shifman, {Sophie G.} and Ivana Sarotto and Peter Savas and Wick, {Michael J.} and Papadopoulos, {Kyriakos P.} and Alyssa Moriarty and Cutler, {Richard E.} and Francesca Avogadri-Connors and Lalani, {Alshad S.} and Bryce, {Richard P.} and Sarat Chandarlapaty and Hyman, {David M.} and Solit, {David B.} and Valentina Boni and Sherene Loi and Jos{\'e} Baselga and Berger, {Michael F.} and Filippo Montemurro and Maurizio Scaltriti",
year = "2018",
month = "10",
day = "9",
doi = "10.1126/scisignal.aat9773",
language = "English",
volume = "11",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "551",

}

TY - JOUR

T1 - Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

AU - Cocco, Emiliano

AU - Carmona, F. Javier

AU - Razavi, Pedram

AU - Won, Helen H.

AU - Cai, Yanyan

AU - Rossi, Valentina

AU - Chan, Carmen

AU - Cownie, James

AU - Soong, Joanne

AU - Toska, Eneda

AU - Shifman, Sophie G.

AU - Sarotto, Ivana

AU - Savas, Peter

AU - Wick, Michael J.

AU - Papadopoulos, Kyriakos P.

AU - Moriarty, Alyssa

AU - Cutler, Richard E.

AU - Avogadri-Connors, Francesca

AU - Lalani, Alshad S.

AU - Bryce, Richard P.

AU - Chandarlapaty, Sarat

AU - Hyman, David M.

AU - Solit, David B.

AU - Boni, Valentina

AU - Loi, Sherene

AU - Baselga, José

AU - Berger, Michael F.

AU - Montemurro, Filippo

AU - Scaltriti, Maurizio

PY - 2018/10/9

Y1 - 2018/10/9

N2 - Mutations in ERBB2, the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of "HER2-negative" (not ERBB2 amplified) tumors but are rare in "HER2-positive" (ERBB2 amplified) breast cancer. We analyzed DNA-sequencing data from HER2-positive patients and used cell lines and a patient-derived xenograft model to test the consequence of HER2 mutations on the efficacy of anti-HER2 agents such as trastuzumab, lapatinib, and neratinib, an irreversible pan-EGFR inhibitor. HER2 mutations were present in ~7% of HER2-positive tumors, all of which were metastatic but not all were previously treated. Compared to HER2 amplification alone, in both patients and cultured cell lines, the co-occurrence of HER2 mutation and amplification was associated with poor response to trastuzumab and lapatinib, the standard-of-care anti-HER2 agents. In mice, xenografts established from a patient whose HER2-positive tumor acquired a D769Y mutation in HER2 after progression on trastuzumab-based therapy were resistant to trastuzumab or lapatinib but were sensitive to neratinib. Clinical data revealed that six heavily pretreated patients with tumors bearing coincident HER2 amplification and mutation subsequently exhibited a statistically significant response to neratinib monotherapy. Thus, these findings indicate that coincident HER2 mutation reduces the efficacy of therapies commonly used to treat HER2-positive breast cancer, particularly in metastatic and previously HER2 inhibitor-treated patients, as well as potentially in patients scheduled for first-line treatment. Therefore, we propose that clinical studies testing the efficacy of neratinib are warranted selectively in breast cancer patients whose tumors carry both amplification and mutation of ERBB2/HER2.

AB - Mutations in ERBB2, the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of "HER2-negative" (not ERBB2 amplified) tumors but are rare in "HER2-positive" (ERBB2 amplified) breast cancer. We analyzed DNA-sequencing data from HER2-positive patients and used cell lines and a patient-derived xenograft model to test the consequence of HER2 mutations on the efficacy of anti-HER2 agents such as trastuzumab, lapatinib, and neratinib, an irreversible pan-EGFR inhibitor. HER2 mutations were present in ~7% of HER2-positive tumors, all of which were metastatic but not all were previously treated. Compared to HER2 amplification alone, in both patients and cultured cell lines, the co-occurrence of HER2 mutation and amplification was associated with poor response to trastuzumab and lapatinib, the standard-of-care anti-HER2 agents. In mice, xenografts established from a patient whose HER2-positive tumor acquired a D769Y mutation in HER2 after progression on trastuzumab-based therapy were resistant to trastuzumab or lapatinib but were sensitive to neratinib. Clinical data revealed that six heavily pretreated patients with tumors bearing coincident HER2 amplification and mutation subsequently exhibited a statistically significant response to neratinib monotherapy. Thus, these findings indicate that coincident HER2 mutation reduces the efficacy of therapies commonly used to treat HER2-positive breast cancer, particularly in metastatic and previously HER2 inhibitor-treated patients, as well as potentially in patients scheduled for first-line treatment. Therefore, we propose that clinical studies testing the efficacy of neratinib are warranted selectively in breast cancer patients whose tumors carry both amplification and mutation of ERBB2/HER2.

UR - http://www.scopus.com/inward/record.url?scp=85054778916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054778916&partnerID=8YFLogxK

U2 - 10.1126/scisignal.aat9773

DO - 10.1126/scisignal.aat9773

M3 - Article

C2 - 30301790

AN - SCOPUS:85054778916

VL - 11

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 551

M1 - eaat9773

ER -